GlassScriptPhysician profile
Grant Thomas Bischof
NPI 1306467709
$25,146.74
in general payments reported to CMS, 2019-2025
65 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $613 · 2022: $1,934 · 2023: $3,362 · 2024: $3,800 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $189 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,492.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,830.69 |
| Travel and Lodging | $189.00 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,377.87 | 2021-2025 | |
| Tg Therapeutics, INC. | $1,135.74 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $761.78 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Pfizer INC. | $719.33 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $714.92 | 2021-2025 | |
| Ucb, INC. | $627.65 | 2021-2025 | Briviact, Rystiggo, Zilbrysq |
| Jazz Pharmaceuticals INC. | $604.27 | 2022-2025 | |
| Lilly USA, LLC | $602.72 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Celgene Corporation | $553.96 | 2022-2025 | Zeposia |
| Argenx US, INC. | $504.58 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $438.46 | 2022-2025 | Vumerity, Tysabri, Leqembi |
| Amgen INC. | $408.66 | 2021-2025 | Uplizna, Aimovig |
| Amneal Pharmaceuticals LLC | $393.04 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Lundbeck LLC | $308.33 | 2023-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $299.90 | 2023-2025 | Mavenclad |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $286.30 | 2021-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $256.15 | 2022-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $249.51 | 2023-2025 | Gocovri, Gocovri, Apokyn |
| Takeda Pharmaceuticals U.S.A., INC. | $246.57 | 2021-2025 | Hyqvia, Gammagard |
| Grifols USA, LLC | $245.29 | 2022-2025 | Gamunex-C, Hyperrab |
| Otsuka America Pharmaceutical, INC. | $232.89 | 2023-2025 | Rexulti, Nuedexta |
| Neurelis, INC. | $215.93 | 2023-2025 | Valtoco |
| Axsome Therapeutics, INC. | $210.90 | 2024-2025 | Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $203.68 | 2022 | |
| Acorda Therapeutics, INC | $172.80 | 2022-2023 | Inbrija |
| Genentech USA, INC. | $167.64 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Eisai INC. | $149.38 | 2023-2025 | |
| Avion Pharmaceuticals | $133.23 | 2022-2023 | Dhivy |
| Supernus Pharmaceuticals, INC. | $122.24 | 2021-2023 | Gocovri |
| Biohaven Pharmaceuticals, INC. | $110.85 | 2021 | |
| Kyowa Kirin, INC. | $108.90 | 2021-2023 | Nourianz |
| Upsher-Smith Laboratories LLC | $100.21 | 2021-2022 | |
| Kedrion Biopharma, INC. | $96.77 | 2024-2025 | Albuked, Koate, Rhogam Ultra-Filtered Plus |
| Corium, LLC | $94.14 | 2022-2023 | Adlarity |
| Alexion Pharmaceuticals, INC. | $87.63 | 2023-2024 | Ultomiris, Soliris |
| Banner Life Sciences, LLC | $83.05 | 2023-2024 | |
| Genzyme Corporation | $77.16 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $69.70 | 2023-2024 | Aptiom |
| Csl Behring | $64.58 | 2023-2024 | Hizentra |
| Impel Pharmaceuticals INC. | $64.10 | 2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $62.57 | 2023-2025 | Onpattro |
| Vertex Pharmaceuticals Incorporated | $59.94 | 2025 | |
| Aucta Pharmaceuticals, INC. | $58.70 | 2025 | Motpoly Xr |
| Ani Pharmaceuticals, INC. | $57.00 | 2022-2023 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $56.43 | 2023-2024 | Wainua, Evusheld |
| Insightec,INC | $55.81 | 2023 | Exablate |
| Harmony Biosciences LLC | $51.28 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $47.17 | 2024 | |
| Sk Life Science, INC. | $43.67 | 2024-2025 | |
| Inspire Medical Systems, INC. | $42.09 | 2023-2025 | Inspire |
| Greenwich Biosciences, INC. | $33.65 | 2021 | |
| Nevro Corp. | $30.14 | 2022 | |
| Mallinckrodt Hospital Products INC. | $28.37 | 2021-2024 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $27.35 | 2024 | Lumryz |
| E.R. Squibb & Sons, L.L.C. | $26.20 | 2024 | Zeposia |
| Horizon Therapeutics Plc | $22.26 | 2023 | Uplizna |
| Azurity Pharmaceuticals, INC. | $20.44 | 2024 | Horizant |
| Philips North America LLC | $19.17 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.04 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $16.97 | 2022 | |
| Octapharma USA, INC. | $15.59 | 2023 | Panzyga |
| Adamas Pharmaceuticals, INC. | $14.02 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.37 | 2022 | |
| Grt US Holding, INC. | $8.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Bischof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.